Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Carcinoma, Transitional Cell 15Neoplasms 14Ovarian Neoplasms 13Carcinoma, Renal Cell 13Urinary Bladder Neoplasms 12Carcinoma, Merkel Cell 12Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Melanoma 7Stomach Neoplasms 6Recurrence 5Breast Neoplasms 5Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Lymphoma, Non-Hodgkin 2Kidney Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Uveal Melanoma 1Urothelial Cancer 1

Interventions

Injections 2Infusions, Intravenous 2tislelizumab 1sacituzumab govitecan 1bintrafusp alfa protein, human 1avelumab 1Platinum 1Gemcitabine 1DOXO-EMCH 1Cetuximab 1(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Solid Tumors × avelumab × Clear all
NCT03523390 2024-02-23

Phase I/Ib Multiple Ascending Dose Study in China

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
24 enrolled 24 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡